全文获取类型
收费全文 | 8521篇 |
免费 | 524篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 126篇 |
儿科学 | 264篇 |
妇产科学 | 263篇 |
基础医学 | 877篇 |
口腔科学 | 139篇 |
临床医学 | 778篇 |
内科学 | 2224篇 |
皮肤病学 | 80篇 |
神经病学 | 838篇 |
特种医学 | 327篇 |
外科学 | 942篇 |
综合类 | 93篇 |
一般理论 | 6篇 |
预防医学 | 984篇 |
眼科学 | 157篇 |
药学 | 559篇 |
中国医学 | 2篇 |
肿瘤学 | 412篇 |
出版年
2023年 | 32篇 |
2022年 | 45篇 |
2021年 | 174篇 |
2020年 | 83篇 |
2019年 | 167篇 |
2018年 | 190篇 |
2017年 | 159篇 |
2016年 | 145篇 |
2015年 | 170篇 |
2014年 | 279篇 |
2013年 | 389篇 |
2012年 | 629篇 |
2011年 | 688篇 |
2010年 | 377篇 |
2009年 | 372篇 |
2008年 | 567篇 |
2007年 | 687篇 |
2006年 | 639篇 |
2005年 | 613篇 |
2004年 | 577篇 |
2003年 | 527篇 |
2002年 | 463篇 |
2001年 | 98篇 |
2000年 | 67篇 |
1999年 | 80篇 |
1998年 | 103篇 |
1997年 | 75篇 |
1996年 | 59篇 |
1995年 | 68篇 |
1994年 | 47篇 |
1993年 | 46篇 |
1992年 | 48篇 |
1991年 | 29篇 |
1990年 | 37篇 |
1989年 | 60篇 |
1988年 | 35篇 |
1987年 | 23篇 |
1986年 | 21篇 |
1985年 | 17篇 |
1984年 | 30篇 |
1983年 | 20篇 |
1982年 | 23篇 |
1981年 | 18篇 |
1980年 | 16篇 |
1979年 | 7篇 |
1978年 | 14篇 |
1977年 | 11篇 |
1976年 | 9篇 |
1974年 | 6篇 |
1971年 | 6篇 |
排序方式: 共有9071条查询结果,搜索用时 78 毫秒
991.
Rha SW Kuchulakanti PK Pakala R Cheneau E Pinnow E Torguson R Pichard AD Satler LF Suddath WO Kent KM Lindsay J Waksman R 《The American journal of cardiology》2005,96(1):67-70
Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions, and data on its usage in saphenous vein graft interventions are limited. This retrospective, observational study evaluated the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients who underwent saphenous vein graft intervention with distal protection devices. We found that bivalirudin use is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin. 相似文献
992.
Yaka R Thornton C Vagts AJ Phamluong K Bonci A Ron D 《Proceedings of the National Academy of Sciences of the United States of America》2002,99(8):5710-5715
Phosphorylation regulates the function of ligand-gated ion channels such as the N-methyl d-aspartate (NMDA) receptor. Here we report a mechanism for modulation of the phosphorylation state and function of the NMDA receptor via an inhibitory scaffolding protein, RACK1. We found that RACK1 binds both the NR2B subunit of the NMDA receptor and the nonreceptor protein tyrosine kinase, Fyn. RACK1 inhibits Fyn phosphorylation of NR2B and decreases NMDA receptor-mediated currents in CA1 hippocampal slices. Peptides that disrupt the interactions between RACK1, NR2B, and Fyn induce phosphorylation and potentiate NMDA receptor-mediated currents. Therefore, RACK1 is a regulator of NMDA receptor function and may play a role in synaptic plasticity, addiction, learning, and memory. 相似文献
993.
Rebecca Anhang Price Marc N. Elliott Paul D. Cleary Alan M. Zaslavsky Ron D. Hays 《Journal of general internal medicine》2015,30(2):253-256
Measures of patients’ care experiences are increasingly used as quality measures in accountability initiatives. As the prominence and financial impact of patient experience measures have increased, so too have concerns about the relevance and fairness of including them as indicators of health care quality. Using evidence from the Consumer Assessment of Healthcare Providers and Systems (CAHPS®) surveys, the most widely used patient experience measures in the United States, we address seven common critiques of patient experience measures: (1) consumers do not have the expertise needed to evaluate care quality; (2) patient “satisfaction” is subjective and thus not valid or actionable; (3) increasing emphasis on improving patient experiences encourages health care providers and plans to fulfill patient desires, leading to care that is inappropriate, ineffective, and/or inefficient; (4) there is a trade-off between providing good patient experiences and providing high-quality clinical care; (5) patient scores cannot be fairly compared across health care providers or plans due to factors beyond providers’ control; (6) response rates to patient experience surveys are low, or responses reflect only patients with extreme experiences; and (7) there are faster, cheaper, and more customized ways to survey patients than the standardized approaches mandated by federal accountability initiatives.KEY WORDS: patient satisfaction, performance measurement, quality assessment, patient-centered care 相似文献
994.
Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
995.
Oleg Butovsky PhD Mark P. Jedrychowski PhD Ron Cialic PhD MD Susanne Krasemann PhD Gopal Murugaiyan PhD Zain Fanek BSc David J. Greco BSc Pauline M. Wu BSc Camille E. Doykan BSc Olga Kiner MSc Robert J. Lawson BSc Matthew P. Frosch MD Nathalie Pochet PhD Rachid El Fatimy PhD Anna M. Krichevsky PhD Steven P. Gygi PhD Hans Lassmann MD James Berry MD Merit E. Cudkowicz MD Howard L. Weiner MD 《Annals of neurology》2015,77(1):75-99
996.
Pascal Buijs Stefan van Nieuwkoop Vincent Vaes Ron Fouchier Casper van Eijck Bernadette van den Hoogen 《Viruses》2015,7(6):2980-2998
Oncolytic Newcastle disease virus (NDV) might be a promising new therapeutic agent for the treatment of pancreatic cancer. We evaluated recombinant NDVs (rNDVs) expressing interferon (rNDV-hIFNβ-F0) or an IFN antagonistic protein (rNDV-NS1-F0), as well as rNDV with increased virulence (rNDV-F3aa) for oncolytic efficacy in human pancreatic adenocarcinoma cells. Expression of additional proteins did not hamper virus replication or cytotoxic effects on itself. However, expression of interferon, but not NS1, resulted in loss of multicycle replication. Conversely, increasing the virulence (rNDV-F3aa) resulted in enhanced replication of the virus. Type I interferon was produced in high amounts by all tumor cells inoculated with rNDV-hIFNβ-F0, while inoculation with rNDV-NS1-F0 resulted in a complete block of interferon production in most cells. Inoculation of human pancreatic adenocarcinoma cells with rNDV-F3aa caused markedly more cytotoxicity compared to rNDV-F0, while inoculation with rNDV-hIFNβ-F0 and rNDV-NS1-F0 induced cytotoxic effects comparable to those induced by the parental rNDV-F0. Evaluation in vivo using mice bearing subcutaneous pancreatic cancer xenografts revealed that only intratumoral injection with rNDV-F3aa resulted in regression of tumors. We conclude that although lentogenic rNDVs harboring proteins that modulate the type I interferon pathway proteins do have an oncolytic effect, a more virulent mesogenic rNDV might be needed to improve oncolytic efficacy. 相似文献
997.
Rutger-Jan Nuis Gokhan Turgut Robert M van der Boon Nicolas M Van Mieghem Sjoerd T Naut Patrick W Serruys Ron T van Domburg Giulio Zuchelli Luc Jordaens Peter P de Jaegere 《老年心脏病学杂志》2015,12(5):482-488
Background Corrected QT dispersion (cQTD) has been correlated with non-uniform ventricular repolarisation and increased mortality. In patients with aortic stenosis, cQTD has been shown improved after surgical valve replacement, but the effects of transcatheter aortic valve implantation (TAVI) are unknown. Therefore, we sought to explore the frequency, predictors and prognostic effects of defective cQTD recovery at 6 months after TAVI. Methods A total of 222 patients underwent TAVI with the Medtronic-CoreValve System between November 2005 and January 2012. Patients who were on classⅠor Ⅲ antiarrhythmics or on chronic haemodialysis or who developed atrial fibrillation, a new bundle branch block or became pacemaker dependent after TAVI were excluded. As a result, pre-, post- and follow-up ECG (median: 6 months) analysis was available in 45 eligible patients. Defective cQTD recovery was defined as any progression beyond the baseline cQTD at 6 months. Results In the 45 patients, the mean cQTD was 47 ± 23 ms at baseline, 45 ± 17 ms immediately after TAVI and 40 ± 16 ms at 6 months (15% reduction, P = 0.049). Compared to baseline, cQTD at 6 months was improved in 60% of the patients whereas defective cQTD recovery was present in 40%. cQTD increase immediately after TAVI was an independent predictor of defective cQTD recovery at 6 months (per 10 ms increase; OR: 1.89, 95% CI: 1.15–3.12). By univariable analysis, defective cQTD recovery was associated with late mortality (HR: 1.52, 95% CI: 1.05–2.17). Conclusions Despite a gradual reduction of cQTD after TAVI, 40% of the patients had defective recovery at 6 months which was associated with late mortality. More detailed ECG analysis after TAVI may help to avoid late death. 相似文献
998.
Vicki Modell Jessica Quinn Grant Ginsberg Ron Gladue Jordan Orange Fred Modell 《Immunologic research》2017,65(3):713-720
This study seeks to generate analytic insights into risk management and probability of an identifiable primary immunodeficiency defect. The Jeffrey Modell Centers Network database, Jeffrey Modell Foundation’s 10 Warning Signs, the 4 Stages of Testing Algorithm, physician-reported clinical outcomes, programs of physician education and public awareness, the SPIRIT® Analyzer, and newborn screening, taken together, generates P values of less than 0.05%. This indicates that the data results do not occur by chance, and that there is a better than 95% probability that the data are valid. The objectives are to improve patients’ quality of life, while generating significant reduction of costs. The advances of the world’s experts aligned with these JMF programs can generate analytic insights as to risk management and probability of an identifiable primary immunodeficiency defect. This strategy reduces the uncertainties related to primary immunodeficiency risks, as we can screen, test, identify, and treat undiagnosed patients. We can also address regional differences and prevalence, age, gender, treatment modalities, and sites of care, as well as economic benefits. These tools support high net benefits, substantial financial savings, and significant reduction of costs. All stakeholders, including patients, clinicians, pharmaceutical companies, third party payers, and government healthcare agencies, must address the earliest possible precise diagnosis, appropriate intervention and treatment, as well as stringent control of healthcare costs through risk assessment and outcome measurement. An affected patient is entitled to nothing less, and stakeholders are responsible to utilize tools currently available. Implementation offers a significant challenge to the entire primary immunodeficiency community. 相似文献
999.
1000.
Petar Bezinovi? Darko Rovi? Nena Ron?evi? Lovorka Bilajac 《Croatian medical journal》2015,56(3):297-305